Strontium-90 beta radiation -Wet AMD

CABERNET is a multicenter, randomized, controlled phase III study that enrolls 450 subjects at 45 clinical centers worldwide.

In this research, patients receive either the standard injection of Lucentis® (ranibizumab) or the radiation plus Lucentis^®(58).

A tiny source of radiation is placed inside the eye near the macula, held there for about 4 minutes and then removed.

The radiation destroys the abnormal blood vessels and prevents the growth of blood vessels to stop the progression of wet macular degeneration vision loss.

The system treats neovascularization of retinal tissue by means of a focal, directional delivery of radiation to the target tissues in the retina.

Using standard vitreoretinal surgical techniques, the sealed radiation source is placed temporarily over the retinal lesion by means of a handheld medical device.

If epiretinal brachytherapy proves successful, it can reduce the number of injections needed to just two injections over a period of 12 months.